SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI) in the present day introduced the pricing of its underwritten public providing of 10,377,359 shares of its frequent inventory at a worth to the general public of $26.50 per share. All of the shares are to be bought by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day choice to buy as much as a further 1,556,603 shares of its frequent inventory. Before deducting the underwriting reductions and commissions and estimated providing bills, Denali Therapeutics expects to obtain complete gross proceeds of roughly $275 million, assuming no train of the underwriters’ choice to buy further shares. The providing is anticipated to shut on or about October 24, 2022, topic to satisfaction of customary closing situations.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC are appearing as joint book-running managers for the providing. Berenberg Capital Markets LLC, Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC are appearing as co-managers for the providing.
Denali Therapeutics filed a Registration Statement on Form S-3, which was routinely efficient upon submitting with the SEC on February 28, 2022, and has filed a preliminary prospectus complement and accompanying prospectus referring to the providing on October 18, 2022. A last prospectus complement and accompanying prospectus referring to the providing will even be filed with the SEC. These paperwork may be accessed without spending a dime by the SEC’s web site at www.sec.gov.
When obtainable, copies of the ultimate prospectus complement and the accompanying prospectus referring to this providing might also be obtained from:
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, phone: 1-866-471-2526, fax: 212-902-9316, electronic mail: [email protected] mail.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, phone: 1-866-803-9204 or by electronic mail: [email protected]; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by phone at (877) 821-7388, or by electronic mail at [email protected].
This press launch doesn’t represent a suggestion to promote or a solicitation of a suggestion to purchase, nor will there be any sale of these securities in any state or different jurisdiction through which such provide, solicitation, or sale can be illegal earlier than registration or qualification below the securities legal guidelines of that state or jurisdiction.
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical firm growing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative ailments. Denali Therapeutics pursues new therapies by rigorously assessing genetically validated targets, engineering supply throughout the BBB and guiding growth by biomarkers that exhibit goal and pathway engagement. Denali Therapeutics relies in South San Francisco.
Forward-Looking Statements
This press launch accommodates forward-looking statements inside the that means of the federal securities legal guidelines. These statements contain dangers and uncertainties that would trigger precise outcomes to vary materially, together with, however not restricted to, whether or not or not Denali Therapeutics will have the ability to elevate capital by the sale of shares of frequent inventory or consummate the providing, the ultimate phrases of the providing, the satisfaction of customary closing situations, prevailing market situations, the anticipated use of the proceeds of the providing which might change consequently of market situations or for different causes, and the affect of normal financial, business or political situations within the United States or internationally. Additional dangers and uncertainties referring to the providing, Denali Therapeutics and its business may be discovered below the heading “Risk Factors” in Denali Therapeutics’ most up-to-date present, quarterly and annual studies filed with the SEC and within the preliminary prospectus complement and accompanying prospectus referring to the providing to be filed with the SEC. Denali Therapeutics assumes no responsibility or obligation to replace or revise any forward-looking statements for any motive.
Investor Relations Contact:
Laura Hansen, Ph.D.
Vice President, Investor Relations
(650) 452-2747
[email protected]
Media Contact:
dna Communications
Angela Salerno-Robin
Senior Vice President, Media Relations, Healthcare
+ 1 212 445 8219
[email protected]
